Inhibition of p53 inhibitors: progress, challenges and perspectives
Gema Sanz(Karolinska Institutet), Galina Selivanova(Karolinska Institutet)
Cited by 137
Related Papers
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2
|Cell Cycle|2011|118
Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
|British Journal of Cancer|2022|23